Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junqi Niu

Showing results (161-170 of 280) with videos related to

Pageof 28
Sort By:
Plos One|February 8, 2017
Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearanceChao Zhang, Rui Hua, Yuanyuan Cui, et al.
Virology Journal|December 20, 2024
Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled designMin Wu, Jiajia Mai, Hong Zhang, et al.
Expert Opinion on Investigational Drugs|January 22, 2026
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drugMengdi Lu, Jing Chen, Hong Zhang, et al.
Gastroenterology Report|June 27, 2025
Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric populationWei Li, Lina Jiang, Meiling Li, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 4, 2026
Early treatment initiation optimizes virologic and liver outcomes in pediatric patients with chronic hepatitis B aged 0-18 yearsLin Chen, Lina Jiang, Bokang Zhao, et al.
Immunologic Research|November 20, 2017
Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 regionRui Hua, Xiaoyu Jiang, Lingxia Qi, et al.
Cellular & Molecular Immunology|February 15, 2017
Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replicationGuangyun Tan, Qingfei Xiao, Hongxiao Song, et al.
Ebiomedicine|July 27, 2019
Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormalityYijin Wang, Huiying Rao, Xiumei Chi, et al.
Scientific Reports|October 28, 2016
HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathwayQianqian Zhang, Yang Wang, Naicui Zhai, et al.
Plos Pathogens|March 22, 2014
Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophagesMoses T Bility, Liang Cheng, Zheng Zhang, et al.
Pageof 28

Showing results (161-170 of 280) with videos related to

Sort By:
Pageof 28
Plos One|February 8, 2017
Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearanceChao Zhang, Rui Hua, Yuanyuan Cui, et al.
Virology Journal|December 20, 2024
Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled designMin Wu, Jiajia Mai, Hong Zhang, et al.
Expert Opinion on Investigational Drugs|January 22, 2026
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drugMengdi Lu, Jing Chen, Hong Zhang, et al.
Gastroenterology Report|June 27, 2025
Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric populationWei Li, Lina Jiang, Meiling Li, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 4, 2026
Early treatment initiation optimizes virologic and liver outcomes in pediatric patients with chronic hepatitis B aged 0-18 yearsLin Chen, Lina Jiang, Bokang Zhao, et al.
Immunologic Research|November 20, 2017
Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 regionRui Hua, Xiaoyu Jiang, Lingxia Qi, et al.
Cellular & Molecular Immunology|February 15, 2017
Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replicationGuangyun Tan, Qingfei Xiao, Hongxiao Song, et al.
Ebiomedicine|July 27, 2019
Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormalityYijin Wang, Huiying Rao, Xiumei Chi, et al.
Scientific Reports|October 28, 2016
HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathwayQianqian Zhang, Yang Wang, Naicui Zhai, et al.
Plos Pathogens|March 22, 2014
Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophagesMoses T Bility, Liang Cheng, Zheng Zhang, et al.
Pageof 28